149 related articles for article (PubMed ID: 36712921)
21. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
22. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
23. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
24. Novel biochemical markers for non-invasive detection of pancreatic cancer.
Hrabák P; Šoupal J; Kalousová M; Krechler T; Vočka M; Hanuš T; Petruželka L; Svačina Š; Žák A; Zima T
Neoplasma; 2022 Mar; 69(2):474-483. PubMed ID: 35144477
[TBL] [Abstract][Full Text] [Related]
25. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
26. Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.
Huang T; Jiang SW; Qin L; Senkowski C; Lyle C; Terry K; Brower S; Chen H; Glasgow W; Wei Y; Li J
Int J Mol Sci; 2015 Jan; 16(2):2956-70. PubMed ID: 25642754
[TBL] [Abstract][Full Text] [Related]
27. A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer.
Mason J; Lundberg E; Jonsson P; Nyström H; Franklin O; Lundin C; Naredi P; Antti H; Sund M; Öhlund D
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361759
[TBL] [Abstract][Full Text] [Related]
28. Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer.
Akashi T; Oimomi H; Nishiyama K; Nakashima M; Arita Y; Sumii T; Kimura T; Ito T; Nawata H; Watanabe T
Pancreas; 2003 Jan; 26(1):49-55. PubMed ID: 12499917
[TBL] [Abstract][Full Text] [Related]
29. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.
Nesteruk K; Levink IJM; de Vries E; Visser IJ; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
Pancreatology; 2022 Jun; 22(5):626-635. PubMed ID: 35613957
[TBL] [Abstract][Full Text] [Related]
30. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Byrling J; Hilmersson KS; Ansari D; Andersson R; Andersson B
Clin Transl Oncol; 2022 Feb; 24(2):297-304. PubMed ID: 34319497
[TBL] [Abstract][Full Text] [Related]
31. Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.
Xue A; Scarlett CJ; Chung L; Butturini G; Scarpa A; Gandy R; Wilson SR; Baxter RC; Smith RC
Br J Cancer; 2010 Jul; 103(3):391-400. PubMed ID: 20588270
[TBL] [Abstract][Full Text] [Related]
32. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
[TBL] [Abstract][Full Text] [Related]
33. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
[TBL] [Abstract][Full Text] [Related]
34. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
35. Circulating natural antibodies against 3'-sialyllactose complement the diagnostic performance of CA19-9 for the early detection of pancreatic ductal adenocarcinoma.
Yamada K; Higashi K; Nagahori H; Saito K
Cancer Biomark; 2020; 27(1):121-128. PubMed ID: 31771041
[TBL] [Abstract][Full Text] [Related]
36. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
37. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-Induced TGFBI as a Serum Biomarker for Laboratory Diagnosis and Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.
Yang L; Cui R; Li Y; Liang K; Ni M; Gu Y
Lab Med; 2020 Jul; 51(4):352-361. PubMed ID: 31626700
[TBL] [Abstract][Full Text] [Related]
39. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.
Mahajan UM; Oehrle B; Sirtl S; Alnatsha A; Goni E; Regel I; Beyer G; Vornhülz M; Vielhauer J; Chromik A; Bahra M; Klein F; Uhl W; Fahlbusch T; Distler M; Weitz J; Grützmann R; Pilarsky C; Weiss FU; Adam MG; Neoptolemos JP; Kalthoff H; Rad R; Christiansen N; Bethan B; Kamlage B; Lerch MM; Mayerle J
Gastroenterology; 2022 Nov; 163(5):1407-1422. PubMed ID: 35870514
[TBL] [Abstract][Full Text] [Related]
40. Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma.
Chen J; Chen LJ; Yang RB; Xia YL; Zhou HC; Wu W; Lu Y; Hu LW; Zhao Y
Med Oncol; 2013; 30(2):583. PubMed ID: 23609192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
